First-pass extracted concept

bazedoxifene

Candidate: toolkit item1 source documents4 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

BAZ

Extracted Explainers

What the tool is doing

Bazedoxifene is presented here as a small-molecule PDI inhibitor that rescues chemically induced oxidative ferroptotic injury in hepatocytes. The abstract links its effect to inhibition of PDI catalytic activity and reduced NOS dimerization, nitric oxide, and reactive oxygen species.

Source 1DOI PubMed

Resources required

Use requires bazedoxifene treatment in cultured hepatocytes or a mouse acetaminophen liver injury model. The reported mechanism depends on a PDI-linked oxidative ferroptosis setting.

Source 1DOI PubMed

What problem it solves

The study uses bazedoxifene to mitigate chemically induced oxidative hepatocyte injury and acetaminophen-induced liver injury. It is positioned as a pharmacologic way to interrupt the PDI-NOS-NO-ROS axis.

Source 1DOI PubMed

What it does not solve

The abstract does not show that bazedoxifene broadly solves all forms of liver injury or ferroptosis outside the reported chemical injury settings. It also does not establish detailed target selectivity or structural binding evidence in the provided text.

Source 1DOI PubMed

Alternatives

The abstract identifies protein disulfide isomerase as a therapeutic target but does not name alternative inhibitors within this paper excerpt. Bazedoxifene is the specific intervention highlighted.

Source 1DOI PubMed

Evidence Snippets

we demonstrated that bazedoxifene (BAZ), a selective estrogen receptor modulator, can strongly rescue chemically induced hepatocyte ferroptosis both in vitro and in vivo by inhibiting PDI's catalytic activity

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1cellular mechanismsupports2026Source 1DOI PubMed

In cultured hepatocytes, bazedoxifene suppresses chemically induced oxidative ferroptosis by inhibiting PDI-mediated nitric oxide synthase dimerization, preventing nitric oxide and reactive oxygen species accumulation.

Quoted textsource-backed

In cultured hepatocytes, BAZ strongly suppresses chemically induced oxidative ferroptosis through inhibiting PDI-mediated nitric oxide synthase dimerization (i.e., catalytic activation), which prevents the accumulation of cellular nitric oxide and reactive oxygen species.

Claim 2in vivo effectsupports2026Source 1DOI PubMed

In a mouse model, bazedoxifene alleviates acetaminophen-induced liver injury, improves serum biochemical parameters, and reduces hepatic lipid peroxidation.

Quoted textsource-backed

Specifically, in the mouse model, BAZ effectively alleviates acetaminophen-induced liver injury, improves serum biochemical parameters, and reduces hepatic lipid peroxidation.

Claim 3mechanism of actionsupports2026Source 1DOI PubMed

Bazedoxifene rescues chemically induced hepatocyte ferroptosis in vitro and in vivo by inhibiting protein disulfide isomerase catalytic activity.

Quoted textsource-backed

we demonstrated that bazedoxifene (BAZ), a selective estrogen receptor modulator, can strongly rescue chemically induced hepatocyte ferroptosis both in vitro and in vivo by inhibiting PDI's catalytic activity

Claim 4mechanistic positioningsupports2026Source 1DOI PubMed

The study establishes bazedoxifene as a PDI inhibitor that mitigates chemically induced oxidative hepatocyte injury through a non-estrogen receptor-dependent mechanism.

Quoted textsource-backed

These findings establish BAZ as a PDI inhibitor capable of mitigating chemically induced oxidative hepatocyte injury through a novel, non-estrogen receptor-dependent mechanism.